Camrelizumab, an Anti-PD-1 Monoclonal Antibody, Plus Carboplatin and Nab-Paclitaxel as First-Line Setting for Extensive-Stage Small-Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis

Abstract

This study aimed to investigate the efficacy, safety, and predictors of camrelizumab combined with carboplatin and nab-paclitaxel as first-line setting for patients with extensive-stage small-cell lung cancer (ES-SCLC). Camrelizumab plus carboplatin and nab-paclitaxel were administrated every 3 weeks for four to six cycles, followed by maintenance camrelizumab until intolerable toxicity or disease progression. The primary endpoint was 6-month progression-free survival (PFS) rate and secondary endpoints were objective response rate (ORR), disease control rate (DCR), PFS, overall survival (OS), and safety. We conducted the whole-exome and transcriptomic sequencing on available tumor samples to explore the potential predictive biomarkers. A total of 60 patients were included. Primary endpoint was met with 6-month PFS rate of 52.2%. The median PFS and OS were 7.1 and 18.1 months, respectively. The confirmed ORR and DCR were 73.3% and 93.3%, respectively. No unexpected adverse events were observed. Exploratory analysis showed that MUC17 alterations or high NEUROG1 expression were correlated with markedly shorter PFS and OS. Deeper investigation of transcriptomic data reveals two subsets with distinct immune features and therapeutic vulnerabilities. Collectively, this trial suggested that camrelizumab plus carboplatin and nab-paclitaxel might be an alternative first-line setting for ES-SCLC. Integration of multiomic data could highlight the complex mechanisms underlying chemo-immunotherapy responses.

Keywords

biomarker / camrelizumab / ES-SCLC / immunotherapy / nab-paclitaxel

References

[1] K. L. Simpson, D. G. Rothwell, F. Blackhall, and C. Dive, “Challenges of Small Cell Lung Cancer Heterogeneity and Phenotypic Plasticity,” Nature Reviews Cancer 25, no. 6 (2025): 447-462.

[2] T. Sen, N. Takahashi, S. Chakraborty, et al., “Emerging Advances in Defining the Molecular and Therapeutic Landscape of Small-Cell Lung Cancer,” Nature Reviews Clinical Oncology 21, no. 8 (2024): 610-627.

[3] H. Sung, J. Ferlay, R. L. Siegel, et al., “Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 71, no. 3 (2021): 209-249.

[4] J. P. van Meerbeeck, D. A. Fennell, and D. K. De Ruysscher, “Small-Cell Lung Cancer,” Lancet 378, no. 9804 (2011): 1741-1755.

[5] J. K. Sabari, B. H. Lok, J. H. Laird, J. T. Poirier, and C. M. Rudin, “Unravelling the Biology of SCLC: Implications for Therapy,” Nature Reviews Clinical Oncology 14, no. 9 (2017): 549-561.

[6] L. E. Gaspar, E. J. McNamara, E. G. Gay, et al., “Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment Over 15 Years,” Clinical Lung Cancer 13, no. 2 (2012): 115-122.

[7] S. Wang, J. Tang, T. Sun, et al., “Survival Changes in Patients With Small Cell Lung Cancer and Disparities Between Different Sexes, Socioeconomic Statuses and Ages,” Scientific Reports 7, no. 1 (2017): 1339.

[8] A. Schwendenwein, Z. Megyesfalvi, N. Barany, et al., “Molecular Profiles of Small Cell Lung Cancer Subtypes: Therapeutic Implications,” Molecular Therapy Oncolytics 20 (2021): 470-483.

[9] A. F. Farago and F. K. Keane, “Current Standards for Clinical Management of Small Cell Lung Cancer,” Translational Lung Cancer Research 7, no. 1 (2018): 69-79.

[10] G. S. Jones, K. Elimian, D. R. Baldwin, R. B. Hubbard, and T. M. McKeever, “A Systematic Review of Survival Following Anti-Cancer Treatment for Small Cell Lung Cancer,” Lung Cancer 141 (2020): 44-55.

[11] I. K. Demedts, K. Y. Vermaelen, and J. P. van Meerbeeck, “Treatment of Extensive-Stage Small Cell Lung Carcinoma: Current Status and Future Prospects,” European Respiratory Journal 35, no. 1 (2010): 202-215.

[12] N. Hanna, P. A. Bunn, C. Langer, et al., “Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer,” Journal of Clinical Oncology 24, no. 13 (2006): 2038-2043.

[13] K. Noda, Y. Nishiwaki, M. Kawahara, et al., “Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Small-Cell Lung Cancer,” New England Journal of Medicine 346, no. 2 (2002): 85-91.

[14] S. V. Liu, M. Reck, A. S. Mansfield, et al., “Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133),” Journal of Clinical Oncology 39, no. 6 (2021): 619-630.

[15] J. W. Goldman, M. Dvorkin, Y. Chen, et al., “Durvalumab, With or Without Tremelimumab, Plus Platinum-Etoposide Versus Platinum-Etoposide Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (Caspian): Updated Results From a Randomised, Controlled, Open-Label, Phase 3 Trial,” Lancet Oncology 22, no. 1 (2021): 51-65.

[16] J. Wang, C. Zhou, W. Yao, et al., “Adebrelimab or Placebo Plus Carboplatin and Etoposide as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer (Capstone-1): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial,” Lancet Oncology 23, no. 6 (2022): 739-747.

[17] C. M. Rudin, M. M. Awad, A. Navarro, et al., “Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III Keynote-604 Study,” Journal of Clinical Oncology 38, no. 21 (2020): 2369-2379.

[18] Y. Cheng, L. Han, L. Wu, et al., “Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The Astrum-005 Randomized Clinical Trial,” JAMA 328, no. 12 (2022): 1223-1232.

[19] Y. Cheng, Y. Fan, Y. Zhao, et al., “Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial,” Journal of Thoracic Oncology 19, no. 7 (2024): 1073-1085.

[20] Y. Cheng, W. Zhang, L. Wu, et al., “Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial,” JAMA Oncology 11, no. 1 (2025): 16-25.

[21] D. Adrianzen Herrera, N. Ashai, R. Perez-Soler, and H. Cheng, “Nanoparticle Albumin Bound-Paclitaxel for Treatment of Advanced Non-Small Cell Lung Cancer: An Evaluation of the Clinical Evidence,” Expert Opinion on Pharmacotherapy 20, no. 1 (2019): 95-102.

[22] H. West, M. McCleod, M. Hussein, et al., “Atezolizumab in Combination With Carboplatin Plus Nab-Paclitaxel Chemotherapy Compared With Chemotherapy Alone as First-Line Treatment for Metastatic Non-Squamous Non-Small-Cell Lung Cancer (IMpower130): A Multicentre, Randomised, Open-Label, Phase 3 Trial,” Lancet Oncology 20, no. 7 (2019): 924-937.

[23] P. Schmid, S. Adams, H. S. Rugo, et al., “Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer,” New England Journal of Medicine 379, no. 22 (2018): 2108-2121.

[24] S. Ren, G. Gao, W. Li, et al., “P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts With Extensive SCLC, a Phase II Single Arm Study (Nct02262897),” Journal of Thoracic Oncology 12, no. 11 (2017): S2046.

[25] Z. Megyesfalvi, C. M. Gay, H. Popper, et al., “Clinical Insights Into Small Cell Lung Cancer: Tumor Heterogeneity, Diagnosis, Therapy, and Future Directions,” CA: A Cancer Journal for Clinicians 73, no. 6 (2023): 620-652.

[26] A. Solta, B. Ernhofer, K. Boettiger, et al., “Small Cells—Big Issues: Biological Implications and Preclinical Advancements in Small Cell Lung Cancer,” Molecular Cancer 23, no. 1 (2024): 41.

[27] C. M. Rudin, E. Brambilla, C. Faivre-Finn, and J. Sage, “Small-Cell Lung Cancer,” Nature Reviews Disease Primers 7, no. 1 (2021): 3.

[28] S. Ren, J. Chen, X. Xu, et al., “Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (Camel-Sq): A Phase 3 Trial,” Journal of Thoracic Oncology 17, no. 4 (2022): 544-557.

[29] L. Paz-Ares, A. Luft, D. Vicente, et al., “Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer,” New England Journal of Medicine 379, no. 21 (2018): 2040-2051.

[30] P. Thomas, O. Castelnau, D. Paillotin, et al., “Phase II Trial of Paclitaxel and Carboplatin in Metastatic Small-Cell Lung Cancer: A Groupe Français De Pneumo-Cancérologie Study,” Journal of Clinical Oncology 19, no. 5 (2001): 1320-1325.

[31] C. Gridelli, L. Manzione, F. Perrone, et al., “Carboplatin Plus Paclitaxel in Extensive Small Cell Lung Cancer: A Multicentre Phase 2 Study,” British Journal of Cancer 84, no. 1 (2001): 38-41.

[32] J. D. Lickliter, H. K. Gan, M. Voskoboynik, et al., “A First-in-Human Dose Finding Study of Camrelizumab in Patients With Advanced or Metastatic Cancer in Australia,” Drug Design, Development and Therapy 14 (2020): 1177-1189.

[33] M. Untch, C. Jackisch, A. Schneeweiss, et al., “Nab-Paclitaxel Versus Solvent-Based Paclitaxel in Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto-GBG 69): A Randomised, Phase 3 Trial,” Lancet Oncology 17, no. 3 (2016): 345-356.

[34] N. Saijo, “The Role of Pharmacoethnicity in the Development of Cytotoxic and Molecular Targeted Drugs in Oncology,” Yonsei Medical Journal 54, no. 1 (2013): 1-14.

[35] L. Horn, A. S. Mansfield, A. Szczęsna, et al., “First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer,” New England Journal of Medicine 379, no. 23 (2018): 2220-2229.

[36] S. Lin, H. Ruan, L. Qin, et al., “Acquired Resistance to EGFR-TKIs in NSCLC Mediates Epigenetic Downregulation of MUC17 by Facilitating NF-κB Activity via UHRF1/DNMT1 Complex,” International Journal of Biological Sciences 19, no. 3 (2023): 832-851.

[37] W. S. Al Amri, L. M. Allinson, D. E. Baxter, et al., “Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer,” Molecular Cancer Therapeutics 19, no. 3 (2020): 945-955.

[38] B. Yang, A. Wu, Y. Hu, et al., “Mucin 17 Inhibits the Progression of Human Gastric Cancer by Limiting Inflammatory Responses Through a MYH9-p53-RhoA Regulatory Feedback Loop,” Journal of Experimental & Clinical Cancer Research 38, no. 1 (2019): 283.

[39] C. P. Wardell, M. Fujita, T. Yamada, et al., “Genomic Characterization of Biliary Tract Cancers Identifies Driver Genes and Predisposing Mutations,” Journal of Hepatology 68, no. 5 (2018): 959-969.

[40] G. C. Machado and V. P. Ferrer, “MUC17 Mutations and Methylation Are Associated With Poor Prognosis in Adult-Type Diffuse Glioma Patients,” Journal of the Neurological Sciences 452 (2023): 120762.

[41] A. Herbst, K. Rahmig, P. Stieber, et al., “Methylation of NEUROG1 in Serum Is a Sensitive Marker for the Detection of Early Colorectal Cancer,” American Journal of Gastroenterology 106, no. 6 (2011): 1110-1118.

[42] J. George, J. S. Lim, S. J. Jang, et al., “Comprehensive Genomic Profiles of Small Cell Lung Cancer,” Nature 524, no. 7563 (2015): 47-53.

[43] C. M. Gay, C. A. Stewart, E. M. Park, et al., “Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC With Distinct Therapeutic Vulnerabilities,” Cancer Cell 39, no. 3 (2021): 346-360.

[44] B. Y. Nabet, H. Hamidi, M. C. Lee, et al., “Immune Heterogeneity in Small-Cell Lung Cancer and Vulnerability to Immune Checkpoint Blockade,” Cancer Cell 42, no. 3 (2024): 429-443.e4.

[45] C. M. Rudin, J. T. Poirier, L. A. Byers, et al., “Molecular Subtypes of Small Cell Lung Cancer: A Synthesis of Human and Mouse Model Data,” Nature Reviews Cancer 19, no. 5 (2019): 289-297.

[46] S. Chen, Y. Zhou, Y. Chen, and J. Gu, “Fastp: An Ultra-Fast All-in-One FASTQ Preprocessor,” Bioinformatics 34, no. 17 (2018): i884-i890.

[47] H. Li, B. Handsaker, A. Wysoker, et al., “The Sequence Alignment/Map Format and SAMtools,” Bioinformatics 25, no. 16 (2009): 2078-2079.

[48] A. McKenna, M. Hanna, E. Banks, et al., “The Genome Analysis Toolkit: A MapReduce Framework for Analyzing Next-Generation DNA Sequencing Data,” Genome Research 20, no. 9 (2010): 1297-1303.

[49] M. A. DePristo, E. Banks, R. Poplin, et al., “A Framework for Variation Discovery and Genotyping Using Next-Generation DNA Sequencing Data,” Nature Genetics 43, no. 5 (2011): 491-498.

[50] A. Mayakonda, D.-C. Lin, Y. Assenov, C. Plass, and H. P. Koeffler, “Maftools: Efficient and Comprehensive Analysis of Somatic Variants in Cancer,” Genome Research 28, no. 11 (2018): 1747-1756.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.